阿尔茨海默病作为神经退行性疾病，已成为威胁老年人健康的"第四大杀手"，是我国面临的重大公共卫 生挑战之一。签约仪式上，上海市中医老年医学研究所郁志华教授对《证券日报》记者表示："我国现 存阿尔茨海默病及其他痴呆患者约1699万例，每年新发291万例。值得注意的是，约75%的患者未能获 得及时诊断，疾病认知与就诊率低，给数千万家庭带来沉重照护负担。" 本报记者 王僖 11月18日上午，山东沃华医药科技股份有限公司（以下简称"沃华医药"）与北京宜从容科技有限公司 （以下简称"宜从容"）在山东潍坊沃华医药举行"参枝苓口服液品牌共建战略合作"签约仪式。根据协 议，双方将整合研发、生产、临床推广与市场渠道资源，共同推动沃华医药独家专利产品——参枝苓口 服液在阿尔茨海默病防治领域的广泛应用，提升中成药在认知障碍全程管理中的临床价值。 此次沃华医药战略牵手宜从容，也是两家企业在医药创新模式上的重要探索。根据合作规划，沃华医药 将依托其生产质量体系与学术推广能力，保障产品供应与医学价值传递；宜从容将发挥其渠道资源、专 业推广与患者服务优势，实现产品在多元市场的精准覆盖与深度渗透。这一"研发—市场—服务"深度融 合模式，有望为 ...

来源：环球网 阿尔茨海默病作为神经退行性疾病，已成为威胁老年人健康的"第四大杀手"，是我国面临的重大公共卫 生挑战之一。签约仪式上，上海市中医老年医学研究所郁志华教授指出："我国现存阿尔茨海默病及其 他痴呆患者约1699万例，每年新发291万例。更值得注意的是，约75%的患者未能获得及时诊断，疾病 认知与就诊率低，为数千万家庭带来沉重照护负担。" 近年来，国家层面连续推出《应对老年期痴呆国家行动计划（2024-2030年）》及其他相关政策，并将 认知功能筛查纳入《成人健康体检项目推荐指引》，推动早筛早诊。这些举措不仅强化了疾病防控体 系，也为相关医药产品带来重要发展机遇。 在此背景下，沃华医药与宜从容携手，共同推动国内为数不多的、获批用于阿尔茨海默病治疗的中成药 ——参枝苓口服液，将更高效地服务于临床与患者。 【环球网财经综合报道】11月18日上午，山东沃华医药科技股份有限公司（以下简称"沃华医药"）与北 京宜从容科技有限公司（以下简称"宜从容"）在山东潍坊沃华医药举行"参枝苓口服液品牌共建战略合 作"签约仪式。沃华医药总裁、营销平台联席总经理李盛廷与宜从容总经理张小平代表双方签署协议。 （图说：沃华医药总裁 ...

Core Insights - The strategic partnership between Wohuamedicine and Yicongrong aims to enhance the application of the patented product, Shen Zhi Ling Oral Liquid, in the prevention and treatment of Alzheimer's disease, thereby increasing the clinical value of traditional Chinese medicine in managing cognitive disorders [1][2][4] Group 1: Alzheimer's Disease Context - Alzheimer's disease poses a significant public health challenge in China, with approximately 16.99 million existing patients and 2.91 million new cases annually, while around 75% of patients do not receive timely diagnosis [2] - National policies, including the "National Action Plan for Dementia (2024-2030)," have been introduced to improve early screening and diagnosis, creating development opportunities for related pharmaceutical products [2] Group 2: Shen Zhi Ling Oral Liquid - Shen Zhi Ling Oral Liquid, developed over 20 years by a team from the Shanghai Institute of Traditional Chinese Medicine, consists of ten herbal ingredients and has received multiple national patents and awards [3] - Clinical studies indicate that Shen Zhi Ling Oral Liquid effectively improves cognitive function and alleviates symptoms associated with Alzheimer's disease, making it the only traditional Chinese medicine approved for this treatment [3] Group 3: Strategic Collaboration - The collaboration represents a significant exploration of innovative pharmaceutical models, aiming to integrate research, market, and service to enhance the product's market presence [4] - Wohuamedicine will leverage its production quality and academic promotion capabilities, while Yicongrong will utilize its marketing and patient service strengths to ensure precise market coverage [4] Group 4: Economic Impact - The partnership is expected to stimulate regional economic development by providing new opportunities for both companies and enhancing the local biopharmaceutical industry [5] - The collaboration aims to contribute to the broader goals of "Healthy China" and "Healthy Aging" by addressing the challenges of Alzheimer's disease through integrated resources and innovative solutions [5]

Core Viewpoint - The divorce settlement between Zhao Bingxian and Lu Juan has resulted in a 50-50 ownership of Zhongzheng Wanrong Investment Group, leading to a governance vacuum for Wohuah Pharmaceutical, which now lacks a controlling shareholder [1] Group 1: Governance Issues - The equal distribution of shares means neither Zhao Bingxian nor Lu Juan can unilaterally control the board or strategic direction, potentially leading to decision-making deadlocks [2] - Key issues such as strategic transformation, major project investments, or executive appointments may become contentious, resulting in governance challenges [2] - Although the company claims that operational management remains unaffected, the dispersed control introduces uncertainty for future stability [2] Group 2: Performance and Growth Concerns - Wohuah Pharmaceutical reported a 179.34% year-on-year increase in net profit for the first three quarters of 2025, primarily driven by non-recurring income from land transfer payments [3] - The core business growth remains weak, with reliance on a limited range of proprietary products amidst increasing regulatory pressures and procurement challenges [3] - The company must address its growth bottlenecks and develop a second growth curve to ensure long-term sustainability [3] Group 3: Industry-Wide Implications - Wohuah Pharmaceutical is not an isolated case; several other companies have faced similar issues due to controlling shareholders' divorces, leading to significant ownership restructuring [4] - These events have raised concerns about the stability of shareholder structures and the management of risks associated with controlling shareholders' personal relationships [4] - As the capital market matures, it is crucial to implement measures such as corporate governance design, equity trusts, and voting rights arrangements to mitigate disruptions caused by personal relationship changes [4] Conclusion - The "no owner" status of Wohuah Pharmaceutical highlights broader governance challenges within A-share companies, emphasizing the need for strategic resilience and operational stability in the face of high volatility and uncertainty in ownership structures [5]

资金流向方面，主力资金净流出71.64万元，特大单买入111.61万元，占比3.07%，卖出0.00元，占比 0.00%；大单买入281.84万元，占比7.76%，卖出465.09万元，占比12.80%。 11月14日，沃华医药（维权）盘中上涨2.16%，截至10:15，报6.62元/股，成交3633.69万元，换手率 0.97%，总市值38.21亿元。 截至9月30日，沃华医药股东户数4.10万，较上期增加17.18%；人均流通股13892股，较上期减少 14.66%。2025年1月-9月，沃华医药实现营业收入6.25亿元，同比增长8.31%；归母净利润6399.50万元， 同比增长179.34%。 分红方面，沃华医药A股上市后累计派现6.92亿元。近三年，累计派现2.14亿元。 机构持仓方面，截止2025年9月30日，沃华医药十大流通股东中，博道久航混合A（008318）位居第八 大流通股东，持股99.89万股，为新进股东。国泰海通中证500指数增强A（014155）位居第十大流通股 东，持股93.12万股，为新进股东。博道远航混合A（007126）退出十大流通股东之列。 责任编辑：小浪快报 沃华医药今年 ...

Core Viewpoint - Wohuah Pharmaceutical announced the convening of its sixth temporary board meeting of the eighth session on November 12, 2025, to discuss the proposal for the fourth temporary shareholders' meeting of 2025 [1] Group 1: Company Financials - For the first half of 2025, Wohuah Pharmaceutical's revenue composition was 100.0% from the pharmaceutical industry [1] - The current market capitalization of Wohuah Pharmaceutical is 3.7 billion yuan [1]

证券代码：002107 证券简称：沃华医药 公告编号：2025-044 山东沃华医药科技股份有限公司 关于拟变更会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 1、拟聘任的会计师事务所：中喜会计师事务所（特殊普通合伙） （以下简称中喜会计师事务所）。 2、原聘任的会计师事务所：永拓会计师事务所（特殊普通合伙） （以下简称永拓会计师事务所）。 3、拟变更会计师事务所的原因：山东沃华医药科技股份有限公 司（以下简称公司）根据自身业务发展及整体审计工作需要，综合考 虑公司经营管理实际，根据相关规定，公司拟聘任中喜会计师事务所 为公司2025年度财务报告及内部控制的外部审计机构。 4、公司已就变更会计师事务所的相关事宜与前后任会计师事务 所进行了沟通，前后任会计师事务所已明确知悉本次变更事项并确认 无异议。公司董事会、审计委员会对本次拟变更审计机构的事项均不 存在异议，该事项尚需提交公司股东会审议。 5、公司拟变更会计师事务所符合财政部、国务院国资委、证监 1 会印发的《国有企业、上市公司选 ...

2、股东会的召集人：董事会 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第四次临时股东会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 28 日 14:00 证券代码：002107 证券简称：沃华医药 公告编号：2025-045 山东沃华医药科技股份有限公司 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 28 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 28 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 ...

证券代码：002107 证券简称：沃华医药 公告编号：2025-043 山东沃华医药科技股份有限公司 第八届董事会第六次（临时）会议决议公告 该公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 山东沃华医药科技股份有限公司（以下简称公司）第八届董事会 第六次（临时）会议于 2025 年 11 月 12 日以通讯表决方式召开，会 议通知于 2025 年 11 月 6 日以书面、电子邮件等方式发出。本次会议 应参会董事 9 名，实际参会董事 9 名。会议由董事长赵丙贤先生召集。 会议的召开符合《公司法》等相关法律法规及《公司章程》的规定。 经与会董事认真审议，本次会议通过了以下决议： 一、会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于 变更会计师事务所的议案》。 决议内容：同意改聘中喜会计师事务所（特殊普通合伙）为公司 2025 年度财务报告及内部控制审计机构，审计费用 90 万元，其中年 报审计费用为 70 万元，内控审计费用为 20 万元。 该议案已经过公司第八届董事会审计委员会 2025 年第六次会议 审议通过，尚需提交公司股东会审议，并自公司股东 ...

Core Viewpoint - A long-standing divorce property dispute involving significant assets and control of a listed company has concluded, resulting in a change of actual control over Wohuamedicine [1][3]. Company Control Change - The court's ruling mandates an equal division of shares in Zhongzheng Wanrong Investment Group, the controlling shareholder of Wohuamedicine, between Zhao Bingxian and his ex-wife Lu Juan, changing the actual control of Wohuamedicine to a state of no actual controller [3][12]. - Zhao Bingxian previously held 80% of Zhongzheng Wanrong, while Lu Juan held 20%. Post-division, both will hold 50% each [3][12]. - The value of the shares transferred to Lu Juan is approximately 547 million yuan, based on Wohuamedicine's market capitalization of 3.648 billion yuan as of November 10, 2025 [3][12]. Company Background - Wohuamedicine, established in 2002 and listed in 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [12]. - The company's core products include Wohuaxin Keshupian, Gushukang capsules/particles, Huo Dan tablets/capsules, and Naoxue Shukouye, which are the main sources of its revenue and profit [12]. Financial Performance - Wohuamedicine has faced declining performance in recent years, with a continuous drop in net profit from 2021 to 2024 due to price reductions of core products and high marketing costs [12][13]. - The revenue from Wohuaxin Keshupian decreased by 22.56% in 2024, significantly impacting overall revenue [13]. - However, there was a turnaround in 2025, with a reported revenue of 625 million yuan, an increase of 8.31%, and a net profit of 63.995 million yuan, up 179.34% year-on-year [13]. Shareholder Dynamics - The number of shareholders in Wohuamedicine decreased from 48,021 to 34,476 between Q1 2021 and Q1 2025, but began to stabilize and increase to 41,003 by September 30, 2025 [13]. - Following the court ruling, Wohuamedicine's stock price remained stable, with slight increases observed after the announcement [14]. Future Outlook - Lu Juan expressed her commitment to improving management and governance within the company, emphasizing the importance of a professional management team and internal governance mechanisms for sustainable development [14]. - She plans to convene a shareholders' meeting to discuss the company's governance and development direction [14].